Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Declines By 40.6%

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 212,600 shares, a decline of 40.6% from the September 30th total of 358,100 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average trading volume of 631,700 shares, the short-interest ratio is presently 0.3 days.

Institutional Trading of Achilles Therapeutics

A number of large investors have recently bought and sold shares of ACHL. XTX Topco Ltd boosted its position in shares of Achilles Therapeutics by 239.4% during the 2nd quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock valued at $42,000 after purchasing an additional 36,441 shares in the last quarter. Ikarian Capital LLC acquired a new position in Achilles Therapeutics during the 1st quarter worth approximately $1,804,000. StemPoint Capital LP acquired a new stake in Achilles Therapeutics in the first quarter valued at approximately $1,732,000. Finally, Acadian Asset Management LLC bought a new stake in Achilles Therapeutics during the 1st quarter valued at $350,000. 56.38% of the stock is currently owned by institutional investors and hedge funds.

Achilles Therapeutics Stock Performance

NASDAQ:ACHL opened at $0.98 on Friday. The stock’s 50-day moving average is $0.87 and its 200-day moving average is $0.85. Achilles Therapeutics has a 1-year low of $0.63 and a 1-year high of $1.76. The stock has a market cap of $40.27 million, a P/E ratio of -0.61 and a beta of 1.36.

Achilles Therapeutics (NASDAQ:ACHL) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.41). As a group, equities analysts forecast that Achilles Therapeutics will post -1.7 EPS for the current year.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.